Centiva Capital’s Anika Therapeutics ANIK Stock Holding History

Centiva Capital’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15,601	Closed	-$291K	–	1768
2023 Q3	$291K	Buy	+15,601	New	+$324K	0.01%	1199

Other funds holding ANIK

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Centiva Capital's ANIK Position: Q4 2023 in Review

Centiva Capital sold out of Anika Therapeutics (ANIK) in Q4 2023, closing a stake of 15,601 shares — an estimated $291K sold.

Centiva Capital first reported a position in ANIK in Q3 2023 and held it in 1 quarter. The position peaked at $291K in Q3 2023. 117 funds tracked by Wall St. Rank hold ANIK as of Q4 2023.

Centiva Capital reported no remaining Anika Therapeutics position as of Q4 2023 after selling out during the quarter.
Centiva Capital sold 15,601 Anika Therapeutics shares in Q4 2023, an estimated $291K.
Centiva Capital first reported a position in Anika Therapeutics in Q3 2023 and held it in 1 quarter.
Centiva Capital's Anika Therapeutics position peaked at $291K in Q3 2023.
117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2023.

Based on Centiva Capital's 13F filing for Q4 2023, filed 14 Feb 2024.